Open access
2,839
Views
20
CrossRef citations to date
0
Altmetric
Research Article
VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristics
Jinsy A. Andrews1 Eleanor and Lou Gehrig ALS Center, Columbia University, New York, NY, USA,
, Merit E. Cudkowicz2 Department of Neurology, Massachussetts General Hospital, Boston, MA, USA,
, Orla Hardiman3 Biomedical Sciences Institute of Neurosciences, The University of Dublin, Dublin, Ireland,
, Lisa Meng4 Cytokinetics, Inc, South San Francisco, CA, USA, and
, Amy Bian4 Cytokinetics, Inc, South San Francisco, CA, USA, and
, Jacqueline Lee4 Cytokinetics, Inc, South San Francisco, CA, USA, and
, Andrew A. Wolff4 Cytokinetics, Inc, South San Francisco, CA, USA, and
, Fady I. Malik4 Cytokinetics, Inc, South San Francisco, CA, USA, and
& Jeremy M. Shefner5 Department of Neurology, Barrow Neurological Institute, Phoenix, AZ, USACorrespondence[email protected]
show all
Pages 259-266
|
Received 04 Aug 2017, Accepted 19 Dec 2017, Published online: 06 Feb 2018
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.